Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Qihan Biotech's Series A Reaches $25.5 Million for Animal-to-Human Transplants

publication date: Sep 23, 2019

Qihan Biotech of Hangzhou added $5.5 million to its Series A funding, bringing the total to $25.5 million. The company will use the funds to advance its use of CRISPR Cas-9 gene editing for xenotransplantation, the use of animal organs as transplants. In July, the company announced a $20 million funding that has now expanded. Qihan, which was founded in November 2017 as an offshoot of US-based eGenesis, plans to grow organs in pigs because human donor organs are in short supply. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital